Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 5/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.37 |
| ▸ | BACE1 | P56817 | 5/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 3/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31319322 | 0.85 | MC4R (0.41) | BRD4FFAR1 | |
| SCHEMBL3970148 | 0.80 | MAP4K4 (0.46) | MAP4K4BRD4 | |
| SCHEMBL27085837 | 0.80 | BRD4 (0.39) | MAP4K4FYNBRD4CHRM3BACE1 | |
| SCHEMBL15803554 | 0.79 | MAPK14 (0.43) | BRD4FFAR1 | |
| SCHEMBL31439827 | 0.74 | BRD4 (0.43) | BRD4 | |
| SCHEMBL5796145 | 0.74 | BRD4 (0.43) | BRD4 | |
| SCHEMBL12320076 | 0.74 | KDR (0.47) | BRD4 | |
| SCHEMBL30293697 | 0.73 | MAP4K4 (0.47) | MAP4K4FYNBRD4BACE1 | |
| SCHEMBL21020958 | 0.73 | MAP4K4 (0.47) | MAP4K4FYNBRD4BACE1 | |
| SCHEMBL31039260 | 0.72 | BRD4 (0.41) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720055-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250011318-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-01-09 | — | — | US | disclosed |
| WO-2024243502-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011318-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | MAP4K4 1307/4885FYN 278/4885BRD4 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.